Effect of Coenzyme Q10 on Gastric cancer

Evaluation the efficacy of Ubiquinon on Angiogenic growth factors in patients with gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016100426390N2

Enrollment

Registered

2016-10-22

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer. Malignant neoplasm of stomach

Interventions

Intervention 1: Patients will experience CoenzymeQ10 200 mg supplementation under supervision of dietition for 3 month intervention group. Intervention 2: Patients in control group will take placebo i

Treatment - Drugs

Patients will experience CoenzymeQ10 200 mg supplementation under supervision of dietition for 3 month intervention group

Patients in control group will take placebo in the same number as intervention group for 3 month.

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 25 to 75 years old; healthy function of liver and kidney; gastric cancer diagnosis. Exclusion criteria: chemotherapy; food supplement or other dietary regimen; diabetes mellitus.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hepatic Growth Factor. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Matrix Metalloproteinase 2. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Plasminogen Activator Inhibitor 1. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Vascular cell adhesion protein 1. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Transforming Growth Factor beta. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Basic Fibroblastic Growth Factor. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.	—

Measure

Time frame

Hepatic Growth Factor. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Matrix Metalloproteinase 2. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Plasminogen Activator Inhibitor 1. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Vascular cell adhesion protein 1. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Transforming Growth Factor beta. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.;Basic Fibroblastic Growth Factor. Timepoint: before and after intervention. Method of measurement: Labaratory Kits,.

—

Secondary

Measure	Time frame
Weight. Timepoint: before and after intervention. Method of measurement: Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ahmadzadeh

Ahwaz Jundishapoor University of Medical Science

crc@ajums.ac.ir+98 61 3374 3285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026